Should we rely on trials with disease- rather than patient-oriented endpoints?

Intensive Care Medicine

Volumn 44, Issue 4, 2018, Pages 464-466

  de Grooth, Harm Jan ^a   Parienti, Jean Jacques ^b,c   Oudemans van Straaten, Heleen M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CAEN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INTENSIVE CARE; MEDICAL RESEARCH; ORGAN DYSFUNCTION SCORE; OUTCOME ASSESSMENT; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SUDDEN CARDIAC DEATH; BIOASSAY; CLINICAL TRIAL (TOPIC); HEALTH STATUS INDICATOR; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE; STANDARDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; ENDPOINT DETERMINATION; HEALTH STATUS INDICATORS; HUMANS; ORGAN DYSFUNCTION SCORES; PATIENT OUTCOME ASSESSMENT; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85020714469     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-017-4859-0     Document Type: Article

References (15)

1. Bucher HC, Guyatt GH, Cook DJ, Evidence-Based Medicine Working Group et al (1999) Users’ guides to the medical literature: XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 282:771–778. doi:10.1001/jama.282.8.771
2. Tibby SM (2010) Does PELOD measure organ dysfunction…and is organ function a valid surrogate for death? Intensive Care Med 36:4–7. doi:10.1007/s00134-009-1712-0
3. Kellum JA, Zarbock A, Nadim MK (2017) What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Med. doi:10.1007/s00134-017-4732-1
4. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) ICH harmonized tripartite guideline: statistical principles for clinical trials E9
6. Rubenfeld GD (2003) Surrogate measures of patient-centered outcomes in critical care. In: Angus DC, Carlet J (eds) Surviving intensive care. Springer, Berlin, pp 169–180
7. Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 324:781–788. doi:10.1056/NEJM199103213241201
8. Stapleton RD, Wang BM, Hudson LD et al (2005) Causes and timing of death in patients with ARDS. Chest 128:525–532. doi:10.1378/chest.128.2.525
9. Afshari A, Brok J, Møller AM, Wetterslev J (2010) Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev. doi:10.1002/14651858.CD002787.pub2
10. Buyse M, Molenberghs G, Burzykowski T et al (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49–67. doi:10.1093/biostatistics/1.1.49
11. Daniels MJ, Hughes MD (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16:1965–1982. doi:10.1002/(SICI)1097-0258(19970915)16:17%3c1965:AID-SIM630%3e3.0.CO;2-M
12. de Grooth H-J, Geenen IL, Girbes AR et al (2017) SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care 21:38. doi:10.1186/s13054-017-1609-1
13. Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167–178
14. Cleophas TJ, Zwinderman AH (2012) Validating surrogate endpoints of clinical trials. In: Statistics applied to clinical studies. Springer, Berlin, pp 569–578
15. Parast L, McDermott MM, Tian L (2016) Robust estimation of the proportion of treatment effect explained by surrogate marker information. Stat Med 35:1637–1653. doi:10.1002/sim.6820